News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mylan Inc. (MYL) Gets Order Blocking GlaxoSmithKline (GSK) and Apotex Corp. Supply, Sale and/or Importing of a Generic Version of Paxil CR


9/22/2010 7:11:36 AM

PITTSBURGH, Sept. 21 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today obtained a temporary restraining order from the U.S. District Court for the District of New Jersey that prohibits Apotex from "using, offering to sell, selling or shipping or otherwise launching or importing" all three strengths of a generic version of GlaxoSmithKline's Paxil CR, Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, 12.5 mg, 25 mg and 37.5 mg. The order also prohibits GlaxoSmithKline from supplying Apotex with a generic version of the product. The order was entered today, and the court has scheduled further hearings on the matter for Oct. 18.

Mylan is currently selling all three strengths of Paroxetine HCl ER.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.


Read at Bloomberg
Read at BusinessWeek
Read at Reuters
Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES